ABOUT US

OVERVIEW

Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Our proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, we are developing a robust pipeline of novel therapies for patients with unmet needs. Our most advanced program is in Phase 2 clinical development.

Management Team
Greg Babcock, PhD.
Vice President, Research

Greg Babcock joined Visterra in 2013 and has over 15 years of experience researching and developing monoclonal antibodies for a variety of disease indications. Previously, Greg served as the Deputy Director of MassBiologics, building and leading the research efforts at the organization. While at MassBiologics, he discovered and developed four human monoclonal antibodies, primarily for infectious disease targets, that were studied in human clinical trials. Two of these antibodies, bezlotoxumab (Zinplava, for the treatment of recurrent C. difficile infection) and RAB1 (Rabishield, post-exposure prophylaxis for rabies virus) have been approved for human use globally and in India, respectively. Greg has authored approximately 50 peer-reviewed publications and numerous patents in the field of monoclonal antibodies.

Greg received his BS in Microbiology from the University of Massachusetts, Amherst and his Ph.D. in Immunology from Tufts University, Sackler School of Graduate Biomedical Sciences where he developed the model for Epstein Barr virus long-term latency in humans. Following his graduate work, he did his post-doctoral training at Harvard Medical School/Dana Farber Cancer Institute studying the biology of HIV co-receptor usage and viral entry.

Jean L. Bender
Vice President, Pharmaceutical Sciences and Technology

Jean Bender joined Visterra in 2018 and has over 25 years of bioprocess engineering experience within the biopharmaceutical industry. Prior to Visterra, Jean served as Senior Director, BioProcess Engineering at Medimmune LLC where she was responsible for process development engineering, scale-up and transfer of drug substance processes to internal and external manufacturing sites. Previously she held roles of increasing responsibility within Genentech Inc., most recently as Principal Engineer in Purification Development in which she was responsible for tech transfer and licensure of monoclonal antibody processes within the Genentech/Roche manufacturing network. She has authored more than 15 publications and presentations within her field and holds a patent for preparing highly concentrated antibodies by ultrafiltration.

Jean received her MS in Chemical Engineering from the University of California, Berkeley and her BS in Chemical Engineering from Lehigh University.

Todd Curtis
Vice President, Finance and Controller

Todd Curtis joined Visterra in 2015 and has more than 10 years of finance and operations leadership experience within the biotechnology and software sectors and an additional 15 years of senior finance experience across several other industries and organizations, from startups to public companies. Prior to joining Visterra, Todd served as Interim CFO and Controller at Mascoma Corporation and in senior financial positions at Cognition Financial Corporation and Fishery Products International, Inc. Prior to joining industry, he was an accountant in the Boston office of Ernst & Young, LLP.

Todd received an MSA/MBA from Northeastern University’s Graduate School of Professional Accounting, and a BS in Mathematics and Economics from Hamilton College in Clinton, New York. Todd is also a licensed CPA.

Chris Kiefer
Chief Administrative Officer, General Counsel and Corporate Secretary

Chris Kiefer joined Visterra in 2017 and has more than 15 years of life science industry and private practice legal experience. Prior to Visterra, Chris served as Associate General Counsel at Momenta Pharmaceuticals and in senior legal positions at Ironwood Pharmaceuticals and Genzyme Corporation. Prior to joining industry, he was a corporate, securities and transactional attorney with the Boston law firm of Palmer & Dodge. Chris has extensive legal experience in the areas of corporate governance, securities law, collaborations and licensing transactions, corporate finance and healthcare law and compliance.

Chris received a JD from Boston University, a MA in Political Science from the University of Illinois at Urbana-Champaign and a BA in Philosophy and Political Science from Westminster College in Fulton, Missouri.

Greg Miller
Chief Business Officer

Greg Miller joined Visterra in 2013 bringing more than a decade of pharmaceutical business development, strategy and general management experience. Prior to Visterra, Greg served as Vice President of Business and Corporate Development at Concert Pharmaceuticals where he secured numerous collaborations related to the company’s drug development platform, including transactions with Avanir Pharmaceuticals, Jazz Pharmaceuticals, and Celgene Corporation, which culminated in the company’s IPO. Previously, he was Senior Director of Business Development and Corporate Strategy at AMAG Pharmaceuticals where he led the efforts in establishing a multi-regional partnership with Takeda Pharmaceuticals. Greg began his pharmaceutical career at Genzyme Corporation in 2002, where he held various roles in business development, licensing, marketing, and reimbursement. Greg has established partnerships in the biopharmaceutical industry generating more than $135 million in upfront payments and over $2.5 billion in potential future milestones.

Greg received a BA in Psychology from Brandeis University, and both an MBA and an MPH from Boston University.

David Oldach, MD, FIDSA
Chief Medical Officer

David Oldach joined Visterra in 2017 and has more than 25 years of experience in the biotechnology industry and academia. Prior to joining Visterra, David served as Chief Medical Officer at Cempra Pharmaceuticals developing antibiotics for multiple indications. Previously he served as Director of Clinical Research at Gilead, working in HCV and HBV antiviral drug development. Prior to joining industry, David was on the faculty of the University of Maryland School of Medicine, serving as Infectious Diseases Division Chief at the Baltimore Veterans Affairs Medical Center, with a joint appointment as investigator in the Institute of Human Virology. David has authored more than 75 manuscripts, invited editorials, and book chapters across a range of disease topics.

David received his M.D., magna cum laude, from the University of Maryland School of Medicine, trained in Internal Medicine at Massachusetts General Hospital and in Infectious Diseases at Johns Hopkins Hospital.

Brian J. G. Pereira, MD
President and Chief Executive Officer

Brian Pereira joined Visterra in 2013 and is a veteran biopharmaceutical and healthcare leader with experience in financing and growing companies. Prior to joining Visterra, Brian served as the President and CEO of AMAG Pharmaceuticals where he raised four financing rounds at increasing valuations, and built the clinical development, manufacturing, supply-chain, and commercial infrastructure for Feraheme. Previously he held senior roles at Tufts Medical Center including President and CEO of a Tufts Medical Center Physician Organization, interim COO, Vice-Chairman for Strategic Development of the Department of Medicine, and staff physician. Brian is Chairman of the Board of Directors of Africa Healthcare Network and of NephroPlus Ltd. Previously, he was the Chairman of the Board of the Harvard-MIT Biomedical Enterprise Program and President and Board member of the National Kidney Foundation. Brian is an Adjunct Professor of Medicine at Tufts University School of Medicine and has authored over 200 published scientific articles.

Brian received his medical degree (MBBS) from St. John’s Medical College, MD (Medicine) and DM (Nephrology) from the Post Graduate Institute, and MBA from Kellogg Graduate School of Management at Northwestern University.

Zachary Shriver, PhD
Chief Scientific Officer

Zachary Shriver joined Visterra in 2009 as Vice President of Research and has over 17 years of experience in the biotechnology industry. Prior to Visterra, Zachary was one of the founding scientists at Momenta Pharmaceuticals and served as its Senior Director of Research Analytics. While at Momenta, Zachary led the development of state-of-the-art analytical techniques to design a number of complex mixture (polysaccharide, polypeptide, and biologics-based) products, supporting multiple INDs and NDAs. Zachary is an inventor on over 50 issued patents and has authored over 80 publications, including original research on the structure and biology of complex polysaccharides, antibody engineering, and describing protein-glycan interactions.

Zachary received his BA in Chemistry, summa cum laude, from Amherst College and his PhD in Applied Biosciences from MIT, where his research focused on sequencing complex polysaccharides through the integration of analytical and bioinformatics-based techniques.

Greg Babcock, PhD.
Vice President, Research
Jean L. Bender
Vice President, Pharmaceutical Sciences and Technology
Todd Curtis
Vice President, Finance and Controller
Chris Kiefer
Chief Administrative Officer, General Counsel and Corporate Secretary
Greg Miller
Chief Business Officer
David Oldach, MD, FIDSA
Chief Medical Officer
Brian J. G. Pereira, MD
President and Chief Executive Officer
Zachary Shriver, PhD
Chief Scientific Officer
TECHNOLOGY
Hierotope® Platform

Visterra’s Hierotope Platform is comprised of novel and differentiated tools and technologies for the development of next-generation antibody-based therapies. Our proprietary platform enables the design and engineering of precision antibodies that target specifically identified epitopes, or regions on a disease target, comprised of highly networked amino acids — what we refer to as “hierotopes” — that we believe play a critical role in the structure, function and/or activity of disease targets.

Unlike traditional antibody discovery approaches that screen antibodies either randomly or against specific disease targets, we begin by identifying and characterizing in silico the hierotope of a selected disease target.

Then, using a combination of computational and experimental tools, such as epitope-paratope modeling, antibody engineering and high-throughput, epitope-specific screening, we are able to design and engineer antibodies with high potency that bind to the identified hierotope with high affinity, and enable the desired disease-modifying therapeutic effects. We believe our platform enables us to produce antibodies that bind to epitopes and modulate disease targets that are not amenable to, or not adequately addressed by, traditional antibody discovery approaches, such as those that have limited surface area, are hard to access and/or have dynamic structures. In addition, our platform enables further modification of antibodies to improve potential therapeutic utility, for example by extending half-life and increasing potency to reduce dosing frequency and increase patient adherence.

Our Hierotope Platform is a fast, accurate and prolific product-engine that has successfully generated a Phase 2 product candidate with demonstrated safety in patients, and several earlier stage product candidates with established proof-of-concept.

READ MORESHOW LESS

The term hierotope is derived from “hiero,” the Greek term for sacred, and “tope,” the Greek term for site. These hierotopes are composed of highly networked amino acids and believed to be important to the structure, function and/or activity of antigens, or disease targets.

Platform approach and applications

Hierotope Platform-Driven Drug Development Approach:

Our Hierotope Platform consists of the following core tools and technologies.

Our Atomic Interaction Network (AIN) Analysis characterizes each amino acid in a protein and identifies those most highly networked or interconnected. AIN Analysis enables identification and characterization of the hierotopes of a selected disease target.

Our DropPair Technology generates and screens millions of natively paired antibodies. The antibodies are screened based on binding and affinity to a selected disease target, as well as other key functions and characteristics. DropPair Technology enables lead candidate selection.

Our VisDock Technology maps paratope-epitope engagement utilizing computational biology and machine learning, as well as experimentally-derived epitope mapping data. Paratopes are the specific area of an antibody that binds to an epitope. VisDock identifies the optimal paratope for the identified hierotope on a disease target.

Our AbMatch Technology computationally identifies and designs de novo antibodies that geometrically complement or “match” the identified hierotope on a disease target. AbMatch enables the design of lead candidates without random screening.

Our ViStar Technology enables us to extend half-life and optimize effector function through Fc engineering of the antibody.

These technologies enable Visterra to optimize monoclonal antibody design and selection, binding, potency, half-life, manufacturability and overall product development, even for the hardest to treat targets.

Hierotope Platform Applications:

We are applying our platform across three categories of antibody-based therapeutic products:

1. Monoclonal Antibodies: Our monoclonal antibody product candidates are designed and engineered to bind to the hierotope, and selectively modulate the biological activity of the disease target.

2. Bispecific Monoclonal Antibodies: For diseases where a therapeutic effect requires binding to two different disease targets, we design and engineer a bispecific monoclonal antibody that binds to both and selectively modulates the biological activity of the disease targets.

3. Antibody-Drug Conjugates (ADCs): ADCs have a monoclonal antibody component and a drug component. The monoclonal antibody attaches to the organism and facilitates the recruitment of the host immune cells which then engulf and kill the organism. The drug component is a bactericidal peptide that directly kills the organism. The resulting ADC delivers the toxic peptide to the target organism and effects direct killing.

publications
Journal Publications

Touti, F et. al. Antibody-Bactericidal Macrocyclic Peptide Conjugates to Target Gram Negative Bacteria. Chembiochem. 2018 Jul 8. doi: 10.1002/cbic.201800295. [Epub ahead of print]

Booth, B et. al. Extending human IgG half-life using structure-guided design. MAbs. 27:1-13. (2018)

Budigi, Y et. al. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein. PLoS Negl Trop Dis. 12(2): e0006209. (2018)

Ong, E et. al. Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates. Antiviral Res. 144: 44-47. (2017)

Ramakrishnan, B et al. A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza. Trends Microbiol. 24(12): 933-943. (2016)

Baranovich, T et. al. The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome. Antimicrob Agents Chemother. 60:2118-2131. (2016)

Wollacott, AM et. al. Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks. EBioMedicine. 5:147-55. (2016)

Shriver, Z; Trevejo, JM; Sasisekharan R. Antibody-Based Strategies to Prevent and Treat Influenza. Front Immunol. 6:315. (2015)

Tharakaraman K, et al. A broadly neutralizing human monoclonal antibody is effective against H7N9. PNAS. 112(35):10890–95. (2015)

Robinson L, et al. Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope. Cell. 162(3):493–504. (2015)

Viswanathan K, et al. Amino acid interaction networks provide a new lens for therapeutic antibody discovery and anti-viral drug optimization. Current Opinion in Virology. 11:122–129. (2015)

Tharakaraman K, et al. Glycan receptor binding of the influenza A virus H7N9 hemagglutinin. Cell. 153(7):1486-93. (2013)

Tharakaraman K, et al. Structural determinants for naturally evolving H5N1 hemagglutinin to switch its receptor specificity. Cell. 153(7):1475-85. (2013)

Artpradit C, et al. Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles. Virus Res. 176(1-2):69-77. (2013)

Tharakaraman K, et al. Antigenically intact hemagglutinin in circulating avian and swine influenza viruses and potential for H3N2 pandemic. Sci Rep. 3:1822. (2013)

Srinivasan K, et al. Quantitative characterization of glycan-receptor binding of H9N2 influenza A virus hemagglutinin. PLoS One. 8(4):e59550. (2013)

Hobbie SN, et al. Modular glycosphere assays for high-throughput functional characterization of influenza viruses.BMC Biotechnol. Apr 15;13:34. (2013)

Tharakaraman K, et al. Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency. Proc Natl Acad Sci USA. 110(17):E1555-64. (2013)

Srinivasan K, et al. Quantitative description of glycan-receptor binding of influenza A virus H7 hemagglutinin. PLoS One. 8(2):e49597. (2013)

Jayaraman A, et al. Glycosylation at Asn91 of H1N1 haemagglutinin affects binding to glycan receptors. Biochem J. 444(3):429-35. (2012)

Aich U, et al. Glycomics-based analysis of chicken red blood cells provides insight into the selectivity of the viral agglutination assay. FEBS J. 278(10):1699-712. (2011)

Jayaraman A, et al. A single base-pair change in 2009 H1N1 hemagglutinin increases human receptor affinity and leads to efficient airborne viral transmission in ferrets. PLoS One. 6(3):e17616. (2011)

Viswanathan K, et al. Determinants of glycan receptor specificity of H2N2 influenza A virus hemagglutinin. PLoS One. 5(10):e13768. (2010)

Viswanathan K, et al. Glycans as receptors for influenza pathogenesis. Glycoconj J. 27(6):561-70. (2010)

Pappas C, et al. Receptor specificity and transmission of H2N2 subtype viruses isolated from the pandemic of 1957. PLoS One. Jun 21;5(6):e11158. (2010)

Hensley SE, et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science. 326(5953):734-6. (2009)

Shriver Z, et al. Context-specific target definition in influenza a virus hemagglutinin-glycan receptor interactions. Chem Biol. Aug 28;16(8):803-14. (2009)

Maines TR, et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science. 325(5939):484-7. (2009)

Soundararajan V, et al. Extrapolating from sequence–the 2009 H1N1 ‘swine’ influenza virus. Nat Biotechnol.27(6):510-3. (2009)

Srinivasan A, et al. Quantitative biochemical rationale for differences in transmissibility of 1918 pandemic influenza A viruses. Proc Natl Acad Sci USA. 105(8):2800-5. (2008)

Chandrasekaran A, et al. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol. 26(1):107-13. (2008)

ADDITIONAL PUBLICATIONSSHOW LESS

Conference Presentations

Developability Considerations in Structure Guided Engineering of Antibodies. K. Viswanathan, B. Booth, D. Wisheart, B. Ramakrishnan, A. Wollacott, Z. Shriver, G. Babcock. Antibody Engineering and Therapeutics. December 2018.

VIS649 reduces serum IgA levels in NHPs dose dependently: PK/PD exposure-response modeling for translation to treatment of IgA Nephropathy. S. Sloan, F. Engler, K. Szretter, J. Myette, K. Narayan, B. Sundaresh, B. Pereira. Kidney Week. November 2018.

Preclinical safety and scalability of VIS649 production for clinical trials for the treatment of IgA Nephropathy. V. Miller, S. Sloan, K. Szretter, J. Myette, K. Deotale, E. Helger, P. Vollmer, B. Pereira. Kidney Week. November 2018.

Assessment of Resistance Development to Therapeutic mAb VIS410 in an International Phase 2a Study (VIS410-202) in Adults with Uncomplicated Influenza A Infection. K. Narayan, B. Sundaresh, E. Helger, S. Smits, R. Jeeninga, D. Oldach, S. Sloan. ISIRV: Advances in Respiratory Virus Therapeutics. November 2018.

A Pre-clinical Evaluation of an APRIL Targeting Antibody Strategy in Grouped ddY Mice and Non-human Primates and Correlation to Pathogenic and Immune-related Mechanisms. J. Myette, T. Kano, H. Suzuki, S. Sloan, Y. Suzuki, B. Pereira. International IgAN Symposium. September 2018.

Safety, Pharmacokinetics and Pharmacodynamics of VIS649, a Humanized Monoclonal IgG2 Targeting APRIL, for the Treatment of IgAN in a GLP Toxicology Study in Cynomolgus Monkeys. S. Sloan, J. Myette, B. Sundaresh, Z. Shriver, D. Oldach, B. Pereira. International IgAN Symposium. September 2018.

Developing Monoclonal Antibodies for Influenza. Z. Shriver. BioProcess International. September 2018.

Developments in Computational-Based Methods for Antibody Design. A. Wollacott. Discovery on Target. September 2018.

Design of a Novel, Glycan Targeting Antimicrobial ADC as a New Therapeutic Strategy for the Treatment of P. aeruginosa Infection. O. Plante. PEGS. May 2018.

Structure-Based Epitope Targeting for Engineering Functional Antibodies Against Nav1.7 for Pain. L Robinson. PEGS. April 2018.

VIS410, a Broad-Spectrum, Anti-Influenza A Monoclonal Antibody in Clinical Development Demonstrates Activity Against Recent Vaccine, Seasonal, and H7N9 Strains of Influenza. K. Narayan, K. Szretter, E. Helger, B. Sundaresh, Z. Shriver, D. Oldach, S. Sloan. ISIRV: 2nd International Meeting on Respiratory Pathogens. March 2018.

Model-based Clinical Efficacy Prediction and Study Design Support for VIS410, a Novel Neutralizing mAb, in Combination with Oseltamivir, in Hospitalized Patients with Influenza A. Y. Xiong, M. Lovern, P. Smith, R. Wada, S. Sloan, E.  Hershberger. ISIRV: 2nd International Meeting on Respiratory Pathogens. March 2018.

Accurate Modeling of Antibody Complexes Using Docking and Deep Mutational Scanning. A. Wollacott, L. Robinson, B. Ramakrishnan, H. Tissire, K.  Viswanathan, G. Babcock, Z. Shriver. CDD for Biologics. December 2017.

Structural Determinants for Modulating Antibody-Fc Receptor Interactions for Half-Life Enhancement and Effector Functions. K. Viswanathan. Antibody Engineering and Therapeutics. December 2017.

Accurate Computational Modeling of Antibody-Antigen Complexes Incorporating Conformational Epitope Mapping by Deep Sequencing of Comprehensive Antigen Libraries. L. Robinson, A. Wollacott, B. Ramakrishnan, H. Tissire, K. Viswanathan, G. Babcock, Z. Shriver. Antibody Engineering and Therapeutics. December 2017.

Antibody-Based Targeting of APRIL As a Therapeutic Strategy in the Treatment of IgA Nephropathy—A Case Study in Grouped ddY Mouse Model. J. Myette, T. Kano, H. Suzuki, H. Adari, K. Deotale, Z. Shriver, B. Pereira, Y. Suzuki. Kidney Week. November 2017.

Discovery and Engineering of VIS649, a First-in-Class Humanized IgG2 Targeting APRIL for the Treatment of IgA Nephropathy. J. Myette, H. Adari, K. Deotale, B. Ramakrishnan, L. Robinson, K. Szretter, A. Wollacott, Z. Shriver, B. Pereira. Kidney Week. November 2017.

Pharmacokinetics/Pharmacodynamics of VIS649, a First-in-Class Humanized IgG2 Targeting APRIL for the Treatment of IgA Nephropathy, in Healthy Cynomolgus Monkeys. K. Szretter, J. Myette, E. Helger, B. Sundaresh, K. Deotale, J. Trevejo, S. Sloan, B. Pereira. Kidney Week. November 2017.

Preclinical Safety Profile of VIS649, a First-in-Class Humanized IgG2 Targeting APRIL for the Treatment of IgA Nephropathy. K. Szretter, J. Myette, E. Helger, J. Trevejo, S. Sloan, B. Pereira. Kidney Week. November 2017.

Targeting P. aeruginosa with an Antibody-drug Conjugate. O. Plante. Superbugs & Superdrugs USA. November 2017.

Design of a Novel ADC against P. aeruginosa. O. Plante. Annual Meeting of the Boston Area Antibiotic Resistance Network. November 2017.

Structure-based Strategy to Develop Therapeutic Antibodies Against NaV1.7 for Pain. L. Robinson. Discovery on Target. September 2017.

Fine Conformational Epitope Mapping on Quaternary Structures: Combining Yeast Display and NGS for anti-APRIL mAb Mapping. L. Robinson, A. Wollacott, B. Ramakrishnan, H. Tissire, K. Viswanathan, J. Myette, G. Babcock, Z. Shriver. PEGS. May 2017.

Designing and Engineering Antibody Therapeutics for Difficult-to-Target Proteins. G. Babcock. America’s Antibody Congress. January 2017.

VIS649: a Highly Potent Anti-APRIL Antibody for the Treatment of IgA Nephropathy. J. Myette, H. Adari, G. Babcock, K. Deotale, K. Viswanathan, A. Wollacott. American Society of Nephrology. November 2016.

Antibody-Based Approaches for Prophylaxis and Treatment of Zika Virus. J. Trevejo. WHO and Wellcome Trust Meeting – Mosquito-Borne Viruses: Can We Build on Commonalities to Pre-empt the Future? Oct 2016.

Anti-Influenza Antibody VIS410 Targets a Broadly Conserved Epitope on Hemagglutinin. K. Viswanathan, S. Sloan, A. Wollacott, K. Szretter, G. Babcock. ID Week. October 2016.

Evaluation of Efficacy and Emergence of Resistance to VIS410, a Human Monoclonal Antibody, in a Human Challenge Model of Infection with a p2009 H1N1 Virus. S. Sloan, G. Babcock, K. Szretter, S. Bedard, C. Hay, J. Williams, E. Hershberger, J. Trevejo. Options for the Control of Influenza IX. Aug 2016.

Monoclonal Antibody Products for Infectious Diseases. K. Viswanathan. America’s Antibody Congress. January 2016.

Development of Immunological Countermeasures for Zika Virus. L. Robinson. Bridging the Sciences: Zika Virus. May 2016.

Review of Antibody-Based Approaches to Prophylaxis and Treatment of Zika Virus. L Robinson, A Wollacott, G Babcock, Z Shriver, J Trevejo. 5th Pan-American Dengue Research Network Meeting. April 2016.

Improved Antibody Docking Using Knowledge Based Approaches. A. Wollacott, B. Ramakrishnan, L. Robinson, G. Babcock, Z. Shriver, K. Viswanathan. Antibody Engineering and Therapeutics Conference. December 2015.

Structure Guided Design of a Potent Anti-Dengue Antibody. L. Robinson, K. Rowley, A. Winnett, B. Ramakrishnan, A. Wollacott, K. Viswanathan, J. Myette, G. Babcock, Z. Shriver. Antibody Engineering and Therapeutics. December 2015.

Design of a Broadly Neutralizing Antibody Targeting Dengue Virus E Protein Domain III. L. Robinson, J. Myette, K. Viswanathan, Z. Shriver, G. Babcock. Courage Foundation Conference. December 2015.

VIS410, a HA-Targeted Human Antibody, Broadly Neutralizes Influenza Isolates with Pandemic Potential. Y. Budigi, K. Viswanathan, G. Babcock, Z. Shriver. Courage Foundation Conference. December 2015.

Engineering of a Full Spectrum Potent Antibody for the Treatment of Dengue. L. Robinson, K. Rowley, T. Koch, H. Tissire, A. Winnett, K. Viswanathan, J. Myette, Z. Shriver, G. Babcock. American Society of Tropical Hygiene Medicine. October 2015.

Identification of Epitopes for the Development of Selective, Functional Antibodies Targeting Sodium Ion Channels. G. Babcock, L. Robinson, N. Boatright, B. Ramakrishnan, K. Rowley, J. Kuniholm, K. Teichert, A. Wollacott , K. Viswanathan and Z. Shriver. Discovery on Target. September 2015.

VIS410 Monoclonal Antibody Demonstrates Potent Efficacy Against Neuraminidase Inhibitors-Susceptible and -Resistant Influenza A (H7N9) Viruses and Protects Mice from Development of ARDS. T Baranovich, J Jones, S Sloan, K Szretter, J Trevejo, P Seiler, R Webby, E Govorkova. ISIRV-AVG Novel Antiviral Therapies for Influenza and other Respiratory Viruses: Bench to Bedside. June 2015.

VIS410, a Broadly Neutralizing Antibody to Influenza A: Characterisation and Potential for ADE. J Trevejo. ISIRV-AVG Novel Antiviral Therapies for Influenza and other Respiratory Viruses: Bench to Bedside. June 2015.

VIS410, a Human Antibody, Broadly Neutralizes Both Group 1 and Group 2 Influenza Viruses. G. Babcock. 3rd Influenza Research and Development Conference. July 2014.

VIS410, a broadly HA-targeting human antibody, neutralizes H5 and H7 isolates with pandemic potential. G Babcock, K Szretter, S Sloan, K Rowley, S Himansu, K Viswanathan, L Robinson, D Barnard, D Ambrosino, Z Shriver. ICAAC. Sep 2013.

VIS410, a Human Antibody, Provides Additive Efficacy when Dosed with Ostelamivir in a Severe Influenza Model. D Ambrosino, S Sloan, G Babcock, K Viswanathan, D Barnard, Z Shriver. Options for the Control of Influenza VIII. Sep 2013.

Therapeutic or prophylactic treatment with an HA-stem antibody (VIS410) limits respiratory droplet transmission of influenza virus in the ferret model. S Lakdawala, M Baz, E Lamirande, S Sloan, K Szretter, K Viswanathan, D Ambrosino, K Subbarao. Options for the Control of Influenza VIII. Sep 2013.

Design of a Broadly Neutralizing Antibody Targeting Influenza. D Ambrosino, Z Shriver, K Viswanathan. ISIRV Severe Influenza: Burden, Pathogenesis and Management. Oct 2012.

Identification and Characterization of Broadly Neutralizing Antibodies Influenza. Z Shriver and K Viswanathan. ID WEEK. Oct 2012.

Design of a Broadly Neutralizing Antibody Targeting Influenza A. Z Shriver and K Viswanathan. ICAAC. Sep 2012.

ADDITIONAL PRESENTATIONSSHOW LESS

PIPELINE

Visterra is focused on developing and commercializing antibody-based therapies for kidney diseases and other chronic diseases and continuing to support the advancement of existing infectious disease programs through partnerships. Our pipeline includes a Phase 2 product candidate with demonstrated safety in patients, and earlier stage programs with established preclinical proof-of-concept.

Kidney diseases

It is estimated that chronic kidney disease (CKD) affects 31 million people in the United States alone, and 1 in 10 people globally. CKD is defined as kidney damage and/or reduced function, where the kidney can no longer clear toxins and waste products from the blood. There are five stages of CKD beginning with Stage 1 or mild disease and ending in Stage 5 or kidney failure requiring dialysis or transplantation.

VIS649

Visterra’s lead kidney disease program, VIS649, is an engineered anti-APRIL monoclonal antibody (mAb) in development for the treatment of Immunoglobulin A Nephropathy (IgAN), also known as ‘Berger’s Disease’, a leading cause of kidney disease worldwide. The annual incidence rate of IgAN has been estimated in scientific literature to be 25 cases per million or 185,000 individuals worldwide each year. There are currently no approved specific therapies for IgAN, which progresses to kidney failure in 20-40% of patients within 20 years of diagnosis, requiring dialysis or kidney transplantation.

IgAN occurs when an abnormal variant of immunoglobulin A (IgA) is produced that induces the formation of antibodies to the abnormal IgA and these immune complexes deposit and accumulate in the kidneys, resulting in progressive kidney damage. VIS649 has demonstrated the ability to bind to and block the actions of A Proliferation Inducing Ligand (APRIL), a cytokine that stimulates the production of the abnormal IgA. Visterra initiated clinical development with VIS649 in late 2018.

INFECTIOUS DISEASES

VIS410

VIS410 is a broadly neutralizing monoclonal antibody in development for the treatment of hospitalized patients with influenza A. VIS410 is active in vitro against circulating human strains of influenza A, and also avian strains with human pandemic potential. According to the CDC, approximately 35 million people suffer from influenza infections in the United States each year, resulting in as many as 400,000 hospitalizations and as many as 49,000 deaths.

VIS410 is designed to terminate the viral replication cycle and is directed against a Hierotope on hemagglutinin, which is a surface protein of influenza viruses used for binding and entry into cells. Visterra successfully completed a Phase 2a challenge study with VIS410 in healthy subjects inoculated with a pandemic H1N1 strain of the influenza A virus and a Phase 2a clinical study in ambulatory patients diagnosed with influenza A (infected with the circulating strains at that time, H1N1 or H3N2) . Based on the results from these studies, the Company has initiated a global Phase 2b clinical trial in hospitalized patients diagnosed with influenza A.

VIS513

VIS513, is a monoclonal antibody in development for the treatment of Dengue, a serious mosquito-borne virus, which in its most severe forms is characterized by uncontrolled bleeding leading to organ failure and death. VIS513 has in vitro and in vivo activity against all four Dengue virus serotypes found globally. Currently there are no specific treatments for Dengue, which impacts an estimated 96 million people annually resulting in approximately 22,000 deaths worldwide.

infectious disease collaborations

Visterra is collaborating with governmental agencies and other third parties to support the
advancement of our existing infectious disease programs:

  • Funding in support of the development of VIS410 is provided under a contract from the U.S. Biomedical Advanced Research and Development Authority, or BARDA, an agency of the U.S. Department of Health and Human Services.
  • VIS513 is being developed and commercialized in collaboration with Serum Institute of
    India Pvt. Ltd.
  • The development of VIS705 is supported with funding from Combating Antibiotic Resistant
    Bacteria Accelerator, or CARB-X.
  • We have received financial support for advancement of infectious disease programs from
    the Bill & Melinda Gates Foundation.
  • We have a collaboration with Vir Technology for multiple infectious disease research programs.

MEDIA

Press Releases

11.15.18
Visterra Presents Data Demonstrating Safety, Tolerability and Positive Clinical Activity Trends of VIS410 in Non-hospitalized Patients with Influenza A

11.08.18
Visterra Initiates Phase 1 Clinical Study of VIS649

09.04.18
Otsuka Pharmaceutical Completes Acquisition of Visterra

07.11.18
Otsuka Pharmaceutical to Acquire Visterra

03.11.18
Visterra to Present New Preclinical Data on VIS410 for Influenza A at the International Meeting on Respiratory Pathogens

02.12.18
Visterra Announces Publication in the Journal PLOS Neglected Tropical Diseases Demonstrating that Novel Antibody, VIS513, Broadly Neutralizes Antibody-Enhanced Dengue Infection in Preclinical Studies

11.01.17
FDA Grants Fast Track Designation to Visterra’s VIS410 for Treatment of Hospitalized Patients with Influenza A

10.31.17
Visterra to Present New Preclinical Results on VIS649, its Antibody for the Treatment of IgA Nephropathy, at the American Society of Nephrology Kidney Week Conference

10.18.17
Visterra Announces Research Collaboration, Exclusive License, and Option Agreement for Infectious Diseases with Vir Biotechnology

10.05.17
Visterra Closes $46.7 Million Series C Financing to Advance Pipeline of Precision Antibody-Based Biological Medicines

03.31.17
Visterra to Present at 16th Annual Needham Healthcare Conference

03.30.17
Visterra Awarded CARB-X Contract to Advance Development of VIS705

01.11.17
Visterra Doses First Patient in Phase 2a Trial for VIS410, its Monoclonal Antibody in Development for the Treatment of Hospitalized Patients with Influenza A

08.24.16
Visterra to Present New Clinical Results of VIS410 at the Options IX for the Control of Influenza Conference

04.21.16
Visterra Appoints Two Industry Leaders to its Board of Directors

02.26.16
Visterra Announces Publication of Clinical Data on VIS410 in the Journal EBioMedicine

10.05.15
Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study

10.05.15
Visterra Awarded Contract Valued at up to $204.5 Million to Advance the Development of VIS410, its Novel Monoclonal Antibody for the Treatment of Influenza A, by the Biomedical Advanced Research and Development Authority (BARDA)

09.09.15
Visterra, Inc. and Serum Institute of India Ltd. Announce Collaboration to Advance VIS513, a Monoclonal Antibody in Development for the Treatment of Dengue, in the Indian Subcontinent

09.02.15
Visterra Announces Appointment of John Weidenbruch as General Counsel

08.18.15
Visterra Announces Publication of Data Demonstrating the Effectiveness of VIS410 Against Seasonal and Potential Pandemic Influenza Strains

07.16.15
Visterra Announces Publication in the Journal, Cell, Demonstrating Novel Antibody, VIS513, Broadly Neutralizes All Four Serotypes of Dengue Virus in Preclinical Studies

06.02.15
Visterra Announces Presentation of Data at International Influenza Meeting on the Efficacy of VIS410 for Treatment of a Deadly Strain of Avian Influenza

05.21.15
Visterra Partners with A*STAR to Develop VIS513, a Monoclonal Antibody for Dengue

10.31.14
Visterra Announces Additions to its Management Team and Board of Directors

10.02.14
Visterra Closes $30 Million Series B Financing to Advance Pipeline of Multiple Products for Infectious Diseases

09.03.14
Visterra to Present Data at ICAAC on VIS513, its Humanized Monoclonal Antibody That Targets a Conserved Site on the Dengue Virus E Protein

01.03.13
Visterra to Present at the 32nd Annual J.P. Morgan Healthcare Conference

12.02.13
Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT

12.02.13
Visterra Closes $8.1 Million Financing and Expands Executive Team to Accelerate Company Growth

09.24.13
Visterra Named One of the "Fierce 15" Leading Biotech Companies of 2013

09.12.13
Visterra Announces an Oral Presentation of VIS410 Data that Showed Neutralization of H5 and H7 Influenza Strains with Pandemic Potential

09.09.13
Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential

07.15.13
Visterra Appoints Brian Pereira, M.D., as President and Chief Executive Officer

11.09.12
Visterra Secures Financing From Gates Foundation and Omega to Close $26M Series A Financing

10.29.12
Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against the H5N1 (Avian Flu) Influenza Strain in Hanoi, Viet Nam

10.20.12
Visterra Presents Data on Broadly Neutralizing Influenza Antibodies at the Infectious Diseases Society of America (IDSA) Meeting

09.11.12
Visterra Signs Antibody Discovery Collaboration Deal With Pfizer

09.10.12
Visterra Presents Preclinical Results that Shows 100% Prevention and Treatment of Influenza with VIS410, a Novel Engineered Human Antibody

SHOW MORESHOW LESS

Media Coverage

10.06.17 | BioWorld Today
Making Music with MIT Tech | Flu Fighters: $46.7M Rocks Visterra, Pieces of APRIL Key in Nephropathy Bid

SHOW MORESHOW LESS

CAREERS

Visterra was acquired by Otsuka Pharmaceutical in September 2018. Visterra continues to operate its business and develop its pipeline as a member of the Otsuka family of companies, retaining its talent and its location in Waltham, Massachusetts.

“Visterra and Otsuka share a common culture of creativity and innovation, and commitment to patients with kidney diseases, cancer and other hard-to-treat diseases. Joining forces with Otsuka provides Visterra the resources, support and commitment to accelerate development of our pipeline and fully realize the potential of our technology platform,”

Brian J. G. Pereira, MD, CEO, Visterra

At Visterra, we foster a collaborative, innovative, and dynamic culture, and a team dedicated to developing single-dose antibody therapies for infectious diseases. In addition to an open, creative, and invigorating work environment, we offer all our employees a competitive salary and benefits package, and we take pride in cultivating personal and professional growth and learning.

For consideration, please submit a cover letter and resume to careers@visterrainc.com.

Open Positions

Associate Director, Program and Alliance Management

Senior Scientist, CMC; Pharmaceutical Sciences and Technology

Scientist/Senior Scientist Therapeutic Antibody Discovery and Characterization

Senior Scientist, Analytical Development, CMC; Pharmaceutical Sciences and Technology

Scientist / Senior Scientist, Antibody Discovery

Scientist / Senior Scientist, Antibody Design and Protein Engineering

Scientist/Sr. Scientist, Bioanalytical Development

QA Senior Compliance Specialist

CONTACT US

Visterra, Inc.
275 2nd Avenue
Waltham, MA 02451
Phone: (617) 498-1070
Fax: (617) 498-1073
info@visterrainc.com

For Business Development and Partnering:
bd@visterrainc.com

For Investors and Media:
ir@visterrainc.com

Back to Top